Where does CORXEL Pharmaceuticals's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across CORXEL Pharmaceuticals's 1 recorded funding rounds.

Premier Alternatives

CORXEL Pharmaceuticals

Drug Discovery · Shanghai, China · Founded 2019 · Privately Held (backing)

Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics. CORXEL Pharmaceuticals is based in Shanghai, China and was founded in 2019. Its last reported valuation was $475 million in Sep 2024. It has raised $452 million across 1 recorded round; the latest was a $287 million Series D1 in Jan 2026.

Last reported valuation

$474.9M

Oct 2026

Priced at

—

Total raised

$451.8M

Last round

Later Stage VC (Series D1)

Jan 2026

Cap table — not yet on record

CORXEL Pharmaceuticals's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of CORXEL Pharmaceuticals with a free account

·The complete investor list: 13 names
·Watch CORXEL Pharmaceuticals: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about CORXEL Pharmaceuticals

Where does CORXEL Pharmaceuticals's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across CORXEL Pharmaceuticals's 1 recorded funding rounds.